Annual Reports

Title

2017 Annual Report

2016 Annual Report

2015 Annual Report

Get help downloading or viewing the above file types

Navigation

Overview
News Releases
Events & Presentations
Stock Details
Financial Reports
- SEC Filings
- Annual Reports
Corporate Governance
AIM Investors
Investor FAQs
Investor Resources

Print Page |

Email Page |

RSS Feeds |

Email Alerts |

IR Contact |

Financial Tear Sheet

About Us

Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.

Recent News

Motif Bio Submits NDA for Iclaprim
June 14, 2018

Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018
June 11, 2018

Motif Bio to present at Jefferies Global Healthcare Conference in New York
May 31, 2018

Navigation

About Motif
Iclaprim
Investors
News Releases
Contact Us

Contact Us

Motif Bio plc
201 Temple Chambers
3-7 Temple Avenue
London EC4Y 0DT
United Kingdom

Motif BioSciences Inc.
125 Park Avenue, 25th Floor
New York, NY 10017
United States
General: info@motifbio.com
Investors: ir@motifbio.com

Home
About
Product Programs
Opportunity
Investors
Contact